Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand

Permsuwan U 1 , Chaiyakunapruk N 2 , Nathisuwan S 3 , Sukonthasarn A 4

Affiliations 

  • 1 Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Electronic address: unchalee.permsuwan@gmail.com
  • 2 School of Pharmacy, Monash University Malaysia, Malaysia; Center of Pharmaceutical Outcomes Research (CPOR), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; School of Population Health, University of Queensland, Brisbane, Australia; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA
  • 3 Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
  • 4 Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Heart Lung Circ, 2015 Sep;24(9):860-8.
PMID: 25837019 DOI: 10.1016/j.hlc.2015.02.018

Abstract

Non-ST elevation acute coronary syndrome (NSTE-ACS) imposes a significant health and economic burden on a society. Anticoagulants are recommended as standard therapy by various clinical practice guidelines. Fondaparinux was introduced and evaluated in a number of large randomised, controlled trials. This study therefore aimed to determine the cost-effectiveness of fondaparinux versus enoxaparin in the treatment of NSTE-ACS in Thailand.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications